LncRNAs signatures in gynecological cancers: ovarian and endometrial cancers.
1/5 보강
Ovarian and endometrial cancers rank among the most common and deadliest cancers affecting women globally.
APA
Elkholey S, Elgharib Y, et al. (2026). LncRNAs signatures in gynecological cancers: ovarian and endometrial cancers.. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 28(2), 387-403. https://doi.org/10.1007/s12094-025-04020-x
MLA
Elkholey S, et al.. "LncRNAs signatures in gynecological cancers: ovarian and endometrial cancers.." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 28, no. 2, 2026, pp. 387-403.
PMID
40790288 ↗
Abstract 한글 요약
Ovarian and endometrial cancers rank among the most common and deadliest cancers affecting women globally. One of the most important factors that impacts patient survival is how early the tumor is detected. Unfortunately, these cancers often present vague symptoms that usually don't show up until the disease is already in an advanced stage. This makes early diagnosis and screening quite difficult. As a result, researchers are actively seeking better diagnostic tools and treatment approaches. In recent years, non-coding RNAs (ncRNAs) have gained significant attention for their key roles in controlling various cellular activities, especially in cancer. Among them, long non-coding RNAs (lncRNAs) are being explored for their potential as therapeutic targets, as well as their usefulness as diagnostic markers and indicators of poor outcomes. This article focuses on how lncRNAs could be crucial in driving or suppressing cell growth, invasion, metastasis, cell death, and resistance to drugs in ovarian and endometrial cancers.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.